Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 8/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALKBH3 | Q96Q83 | 6/20 | 0.47 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.44 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | PKLR | P30613 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3121393 | 0.89 | KDM4E (0.49) | PGRKDM4EALKBH3PKMLMNA | |
| SCHEMBL3119496 | 0.86 | AR (0.50) | PGRKDM4ELMNAMAPTTDP1 | |
| SCHEMBL3112565 | 0.85 | KDM4E (0.55) | KDM4EALKBH3LMNAMAPTTDP1 | |
| SCHEMBL3113813 | 0.83 | KDM4E (0.53) | KDM4EALKBH3MT-CO1MT-CO2LMNA | |
| SCHEMBL3125409 | 0.83 | KDM4E (0.53) | KDM4EALKBH3MT-CO1MT-CO2KIT | |
| SCHEMBL3113740 | 0.81 | KDM4E (0.53) | PGRKDM4EALKBH3MAPTTDP1 | |
| SCHEMBL13248882 | 0.78 | PGR (0.52) | PGRPKMKITLMNAMAPT | |
| SCHEMBL15258736 | 0.77 | KDM4E (0.53) | KDM4EALKBH3PKMLMNAMAPT | |
| SCHEMBL2567565 | 0.73 | KDM4E (0.55) | KDM4EALKBH3MT-CO1MT-CO2MAPT | |
| SCHEMBL15258818 | 0.72 | KDM4E (0.70) | KDM4EALKBH3MT-CO1MT-CO2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179161-A1 | PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179161-A1 | PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179161-A1 | PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179161-A1 | PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS | TREH, TYMP, EPX | PGR 3063/4885KDM4E 4245/4885ALKBH3 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.